Merck to create separate cancer business as Keytruda patent loss looms
#Merck#Keytruda#Cancer Business#Pharmaceutical Restructuring#Patent Loss#Corporate Strategy#Drug Development
📌 Key Takeaways
Merck to split human-health business into cancer and non-oncology divisions
Restructuring response to Keytruda's impending patent loss
Keytruda generates over $30 billion annually, nearly half of Merck's revenue
Merck has tripled its pipeline since 2021 and made major acquisitions
📖 Full Retelling
Merck announced on Monday at its headquarters in Rahway, New Jersey, that it will split its human-health business into two divisions, separating its cancer franchise from its non-oncology medicines as the pharmaceutical giant prepares for the looming loss of exclusivity for its blockbuster drug Keytruda. The restructuring underscores the U.S. drugmaker's push to diversify beyond Keytruda amid the drug's impending patent expiration later this decade. Keytruda, approved for several forms of cancer, is currently the best-selling prescription medicine globally, generating over $30 billion in 2025 and accounting for nearly half of the company's total revenue. The split comes after Merck issued a downbeat 2026 forecast earlier this month, warning of lower-than-expected sales and profits as several legacy drugs approach the end of their exclusivity periods and face increasing generic competition. In response to these challenges, Merck has tripled its pipeline since 2021 and made two major acquisitions last year, purchasing Cidara Therapeutics and Verona Pharma in deals valued at around $10 billion each to broaden its portfolio. Additionally, the company appointed Jannie Oosthuizen as executive vice president and president of the newly formed cancer business, who previously served as senior vice president and president of Merck Human Health U.S.
Merck refers primarily to the German Merck family and three companies founded by the family, including:
the Merck Group, a German chemical, pharmaceutical and life sciences company founded in 1668
Merck Serono (known as EMD Serono in the United States and Canada), a pharmaceutical company headquart...
Pembrolizumab, sold under the brand name Keytruda, is a humanized monoclonal antibody, more specifically a PD-1 inhibitor, used in cancer immunotherapy to treat many types of cancer. It is administered by slow intravenous injection.
Common side effects include fatigue, musculoskeletal pain, decrease...
Merck's decision to split its business signals a strategic shift to protect revenue from its flagship drug Keytruda as patent protection wanes. The move reflects broader industry pressure to diversify as blockbuster drugs face generic competition.
Context & Background
Keytruda accounts for nearly half of Merck's 2025 revenue
Merck is acquiring biotech firms to broaden its pipeline
The company warned of lower sales in its 2026 forecast due to upcoming patent expirations
What Happens Next
Merck will establish a dedicated cancer division led by Jannie Oosthuizen, while non-oncology products will form a separate unit. The split may improve focus on growth areas and could affect investor perception as the company seeks to offset Keytruda's future revenue decline.
Frequently Asked Questions
What is the reason behind Merck's split?
To isolate the cancer business led by Keytruda and better manage the impact of its patent expiry.
How will the split affect Keytruda's revenue?
Keytruda will remain the core of the cancer division, but its share of total revenue may decline as generics enter the market.
Will investors see a change in share price?
Short-term volatility is possible, but the long-term impact depends on the success of the new cancer unit and pipeline development.
What other strategic moves has Merck made?
Merck has acquired Cidara Therapeutics and Verona Pharma to expand its oncology portfolio and is investing in new drug development.
Original Source
In this article MRK Follow your favorite stocks CREATE FREE ACCOUNT Exterior view of the entrance to Merck headquarters on Feb. 05, 2024 in Rahway, New Jersey. Spencer Platt | Getty Images Merck said on Monday it would split its human-health business into two units, creating a division for its cancer franchise led by blockbuster drug Keytruda while grouping its non-oncology medicines separately. The restructuring underscores the U.S. drugmaker's push to diversify beyond Keytruda amid the drug's looming loss of exclusivity later this decade. Keytruda, approved for several forms of cancer, is the best-selling prescription medicine in the world. The treatment generated more than $30 billion in 2025 and accounted for nearly half of the company's total revenue. Merck shares were up 1.4% in premarket trading. The company has tripled its pipeline since 2021 and struck two deals in the $10 billion range last year, buying Cidara Therapeutics and Verona Pharma to broaden its portfolio. The split follows Merck's downbeat 2026 forecast issued earlier this month, where it warned of lower-than-expected sales and profit as several legacy drugs near loss of exclusivity and face generic pressure. Merck also appointed Jannie Oosthuizen as executive vice president and president of the cancer business. Oosthuizen most recently served as senior vice president and president of Merck Human Health U.S., where he led strategy and commercialization for the company's U.S. portfolio. The news of the split was first reported by the Wall Street Journal earlier in the day. Subscribe to CNBC PRO Subscribe to Investing Club Licensing & Reprints CNBC Councils Select Personal Finance Join the CNBC Panel Closed Captioning Digital Products News Releases Internships Corrections About CNBC Site Map Podcasts Careers Help Contact News Tips Got a confidential news tip? We want to hear from you. Get In Touch CNBC Newsletters Sign up for free newsletters and get more CNBC delivered to your ...
